<DOC>
	<DOCNO>NCT02933502</DOCNO>
	<brief_summary>An Open-Label , Safety Study Assess Potential Adrenal Suppression Following Maximal Use DSXS topical product ( Taro Pharmaceuticals U.S.A. , Inc. ) Patients Moderate SevereScalp Psoriasis</brief_summary>
	<brief_title>Safety Study Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product</brief_title>
	<detailed_description>- Evaluate potential DSXS topical product suppress HPA axis function patient moderate severe scalp psoriasis . - Evaluate efficacy parameter adverse event ( AE ) profile DSXS topical product administer patient moderate severe scalp psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male nonpregnant , nonlactating female 1217 year age . Females pregnant , nursing , plan become pregnant duration study , childbearing potential sexually active prepare use appropriate contraceptive method avoid pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>